C6orf105 Inhibitors
Chemical inhibitors of C6orf105 target various points in the calcium signaling pathways to achieve inhibition. Thapsigargin, by inhibiting the sarco/endoplasmic reticulum calcium ATPase (SERCA) pump, disrupts calcium homeostasis, leading to an increase in cytosolic calcium and depletion of calcium stores, which indirectly affects C6orf105's function due to its reliance on regulated calcium levels. Similarly, 2-APB inhibits inositol trisphosphate (IP3) receptors, which are vital for the release of calcium from the endoplasmic reticulum. The inhibition of these receptors by 2-APB alters calcium flux, thereby affecting C6orf105. SKF-96365 hampers receptor-mediated calcium entry channels, reducing calcium influx that C6orf105 requires for its signaling actions. U73122, a phospholipase C inhibitor, prevents the production of IP3, a crucial molecule for calcium release and, consequently, for C6orf105 functionality.
Further, ML-7 targets myosin light chain kinase, which is involved in the pathways C6orf105 operates in, while KN-93 inhibits calmodulin-dependent kinase II (CaMKII), another key player in calcium signaling. Both inhibitors can disrupt the downstream effects necessary for C6orf105 signaling. Xestospongin C, as an IP3 receptor antagonist, blocks the receptor's function, thereby inhibiting the signaling cascade that C6orf105 is a part of. BAPTA-AM chelates intracellular calcium, directly diminishing the calcium ions available for signaling processes involving C6orf105. W-7, by antagonizing calmodulin, impedes the activation of kinases that are necessary for C6orf105's action. Ruthenium Red, an inhibitor of mitochondrial calcium uptake, also blocks various calcium channels, impacting the signaling required for C6orf105. Lastly, verapamil and nimodipine are L-type calcium channel blockers that inhibit the influx of calcium, which is essential for C6orf105-dependent signaling. Each of these inhibitors, by modulating calcium availability or signaling, can affect C6orf105 function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that indirectly inhibits C6orf105 by disrupting calcium homeostasis within the cell. C6orf105 is associated with calcium-dependent signaling pathways, and by preventing the re-uptake of calcium into the sarcoplasmic and endoplasmic reticulum, thapsigargin can lead to the inhibition of C6orf105’s function. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
2-APB acts as an inhibitor of IP3 receptors, which play a crucial role in regulating intracellular calcium levels. C6orf105 is involved in calcium signaling, and the inhibition of IP3 receptors by 2-APB can lead to altered calcium flux, thereby functionally inhibiting the activity of C6orf105. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $101.00 $155.00 $389.00 $643.00 | 2 | |
SKF-96365 inhibits receptor-mediated calcium entry channels, which are integral for the function of C6orf105 as it is implicated in calcium signaling pathways. By inhibiting these channels, SKF-96365 can reduce calcium influx, leading to a functional inhibition of C6orf105. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 is a myosin light chain kinase inhibitor. C6orf105 is part of pathways that involve calcium-mediated activation of myosin light chain kinase. By inhibiting this kinase, ML-7 can affect the downstream signaling required for proper C6orf105 function, leading to its inhibition. | ||||||
Xestospongin C | 88903-69-9 | sc-201505 | 50 µg | $500.00 | 14 | |
Xestospongin C is an IP3 receptor antagonist. Given that C6orf105 functions within calcium-dependent signaling pathways that involve IP3 receptors, blockade of these receptors by Xestospongin C can inhibit the signaling events necessary for C6orf105 activity. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator. By chelating intracellular calcium, BAPTA-AM can inhibit calcium-dependent signaling pathways in which C6orf105 is involved, resulting in functional inhibition of the protein. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is a calmodulin-dependent kinase II (CaMKII) inhibitor. As CaMKII is a key enzyme in calcium signaling pathways and C6orf105 is associated with such pathways, inhibition of CaMKII by KN-93 can disrupt the signaling required for C6orf105 function, leading to its inhibition. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
W-7 is a calmodulin antagonist that can inhibit calcium-calmodulin-dependent protein kinases. Since C6orf105 is involved in calcium signaling, the inhibition of calmodulin by W-7 can impede the activation of downstream kinases necessary for C6orf105’s function, thereby inhibiting the protein. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $184.00 $245.00 | 13 | |
Ruthenium Red is an inhibitor of calcium uptake by mitochondria and also blocks calcium channels. Inhibition of these pathways can lead to a reduction in the intracellular calcium signaling that is crucial for C6orf105 function, thereby inhibiting the protein. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil is an L-type calcium channel blocker. By blocking these channels, verapamil can inhibit the calcium influx necessary for the function of calcium-dependent proteins like C6orf105, resulting in its functional inhibition. | ||||||